GS967 is a potent and selective inhibitor of the voltage-gated sodium channel NaV1.3, with additional activity on other neuronal sodium channel subtypes. Its primary application lies in neuroscience research, particularly in the study of pathological pain and hyperexcitability disorders. Due to its ability to preferentially block persistent sodium currents over transient ones, GS967 is used to investigate the role of aberrant sodium channel activity in conditions such as neuropathic pain, epilepsy, and certain neurodegenerative diseases. In preclinical studies, GS967 has demonstrated efficacy in reducing neuronal hyperexcitability without significantly impairing normal electrical signaling, making it a valuable tool for validating sodium channels as therapeutic targets. It has shown analgesic effects in animal models of chronic pain, including diabetic neuropathy and inflammatory pain, suggesting potential for development into a novel pain therapeutic. Additionally, GS967 is used to probe the mechanisms of seizure generation and propagation in epilepsy models, where modulation of sodium currents can suppress seizure activity. Its selectivity and mode of action also make GS967 a reference compound in electrophysiology experiments, especially in patch-clamp studies assessing channel kinetics and drug effects on neuronal firing patterns. Overall, GS967 serves as both a pharmacological tool and a lead candidate for developing treatments targeting channelopathies involving voltage-gated sodium channels.